Summit Therapeutics says PhaseOut DMD clinical trial did not meet primary endpoint
The AIM-listed pharmaceuticals group said that because of the outcome, it is discontinuing its development of ezutromid and as a…
- Home
- Current features/ Volume 13 Issue 1
- Editorial Archive
- Volume 12 Issue 6
- Volume 12 Issue 5
- Volume 12 Issue 4
- Volume 12 Issue 3
- Volume 12 Issue 2
- Volume 12 Issue 1
- Volume 11 Issue 6
- Volume 11 Issue 5
- Volume 11 Issue 4
- Volume 11 Issue 3
- Volume 11 Issue 2
- Volume 11 Issue 1
- Volume 10 Issue 6
- Volume 10 Issue 5
- Volume 10 Issue 4
- Volume 10 Issue 3
- Volume 10 Issue 2
- Volume 10 Issue 1
- Volume 9 Issue 6
- Volume 9 Issue 5
- Volume 9 Issue 4
- Volume 9 Issue 3
- Volume 9 Issue 2
- Volume 9 Issue 1
- Volume 8 Issue 6
- Volume 8 Issue 5
- Volume 8 Issue 4
- Volume 8 Issue 3
- Volume 8 Issue 2
- Volume 8 Issue 1
- Volumen 8 Issue 1
- Volume 7 Issue 6
- Volume 7 Issue 5
- Volume 7 Issue 4
- Volume 7 issue 3
- Volume 7 Issue 2
- Volume 7 Issue 1
- Volume 6 Issue 6
- Volume 6 Issue 5
- Volume 6 Issue 4
- Volume 6 Issue 3
- Volume 6 Issue 2
- Volume 6 Issue 1
- Volume 5 Issue 6
- Volume 5 Issue 5
- Volume 5 Issue 4
- Volume 5 Issue 3
- Archived Issues
- Industry events
- Company Profile
- Regional News
- eBooks
- Podcast